MA17.07 Durvalumab Plus Anlotinib Versus Durvalumab as Maintenance Treatment in ES-SCLC (DURABLE): A Randomized, Phase 2 Trial

Bo Han; Bin Zhang; Zhong Ren; Chengbin Shi; Paul Kim Ho Chu; Jianliang Zhang; H. Wang; Yuliang Zhao; Gang Xin; Zhi Zhang; Wei Su; Jie Li; Hao Zhong

doi:10.1016/j.jtho.2024.09.225

Related publications

Article2002

Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non–Small-Cell Lung Cancer: A Phase III Randomized Trial

P. Kosmidis, Nick Mylonakis, C. Nicolaides, C. Kalophonos, Epaminontas Samantas, J. Boukovinas, George Fountzilas, Dimosthenis Skarlos, T. Economopoulos, D. Tsavdaridis, Pavlos Papakostas, C. Bacoyiannis, Meletios A Dimopoulos

Article2025

Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial

George Lau, Bruno Sangro, Ann‐Lii Cheng, Masatoshi Kudo, Robin Kate Kelley, Won Young Tak, Antonio Gasbarrini, María Reig, Ho Yeong Lim, David Tougeron, Enrico N. De Toni, Vincent C. Tam, Kabir Mody, Jun Gong, Oxana Crysler, Wattana Sukeepaisarnjaroen, Oleg Lipatov, Manabu Morimoto, Isabelle Archambeaud, Valentina Burgio, Le Thi Tuyet Phuong, Yee Chao, Jean‐Marie Péron, Marie‐Luise Berres, Yoo‐Joung Ko, Di Ran, Mallory Makowsky, Alejandra Negro, Ghassan K. Abou‐Alfa

Article2000

Randomized trial of ?-interferon or dexamethasone as maintenance treatment for multiple myeloma

Raymond Alexanian, Donna Weber, Meletios A Dimopoulos, Kay Delasalle, Terry L. Smith

Article2015

Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma: A randomized phase II trial.

Masafumi Ikeda, Satoshi Shimizu, Tosiya Sato, Manabu Morimoto, Yoshitaka Inaba, Yasushi Kojima, Atsushi Hagihara, Masatoshi Kudo, Shoji Nakamori, Shuichi Kaneko, Rie Sugimoto, Toshiyuki Tahara, Takumi Ohmura, Kohichiroh Yasui, Keiko Sato, Hiroshi Ishii, Junji Furuse, Takuji Okusaka

Article2024

A randomized phase 2 trial of the IO102-IO103 (IDO and PD-L1) cancer vaccine plus pembrolizumab as neoadjuvant/adjuvant treatment of patients with solid tumors.

Georgina V. Long, Robert I. Haddad, Caroline Robert, Laurent Mortier, Dirk Schadendorf, Ravindra Uppaluri, Inge Marie Svane, Philippe Saïag, Annette M. Lim, Ainara Soria Rivas, Richard A Scolyer, Marya Chaney, Cecilie Abildgaard, Qasim Ahmad, François Ringeisen, Diane Opatt McDowell, Barbara Burtness